Kevin McCaffrey

Most Recent Articles by Kevin McCaffrey

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

By

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

Five things for pharma marketers to know: Thursday, November 30, 2017

Five things for pharma marketers to know: Thursday, November 30, 2017

By

FDA releases information on Exondys 51; Sanofi's dengue vaccine faces new restrictions; Kellyanne Conway named opioid czar

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

HHS nominee Alex Azar: Medicare Part B should negotiate drug prices

By

Alex Azar, previously a senior executive at Eli Lilly, proposed granting Part B the authority to negotiate lower prices.

Five things for pharma marketers to know: Tuesday, November 28, 2017

Five things for pharma marketers to know: Tuesday, November 28, 2017

By

FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year

OPDP issues third enforcement letter of 2017

OPDP issues third enforcement letter of 2017

By

The FDA's Office of Prescription Drug Promotion issued a warning letter to Amherst Pharmaceuticals and Magna Pharmaceutical.

More Articles by Kevin McCaffrey